What is Xenocor?
Established in 2016 and headquartered in Salt Lake City, Utah, Xenocor is dedicated to enhancing minimally invasive surgery through its innovative suite of fog-free, disposable surgical laparoscope technologies. The company's offerings are designed for abdominal and thoracic procedures, aiming to improve surgeon visibility and patient outcomes in a critical segment of the healthcare market. The recent enterprise-level funding suggests Xenocor is poised for significant scaling and market penetration.
How much funding has Xenocor raised?
Xenocor has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2023): $10M with participation from Barvest Ventures, Patel Family Investments, Baranco Investments, and GenHenn Venture Fund I
Key Investors in Xenocor
Barvest Ventures
Barvest Ventures is an investment firm that participated in Xenocor's Series A funding round. Their involvement suggests a focus on companies with disruptive technology in the healthcare sector.
Patel Family Investments
Patel Family Investments is a private investment entity that contributed to Xenocor's Series A financing. Their backing indicates an interest in the medical technology and surgical innovation space.
Baranco Investments
Baranco Investments is an investment group that provided capital for Xenocor's Series A round. Their participation highlights a strategic interest in companies advancing surgical procedures.
What's next for Xenocor?
The substantial enterprise-level funding, including a recent major strategic investment, positions Xenocor for accelerated growth and product development. This capital infusion is expected to fuel advancements in their fog-free laparoscope technology, potentially expanding their market reach within both abdominal and thoracic surgical applications. The company's trajectory indicates a move towards broader adoption and further innovation in the minimally invasive surgical device sector.
See full Xenocor company page
